Kiniksa (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa reported Q3 2026 revenue of $286M for ARCALYST, up 58% YoY. The company expects KPL-387 trial data in 2H 2027 and aims for a 2028-2029 launch. ARCALYST penetration in recurrent pericarditis patients reached 23%. Kiniksa forecasts $1B+ in 2026 ARCALYST revenue and is investing in AI-driven patient identification and marketing campaigns. Operating income was $54.2M, net income $47.3M, with $568.8M in cash at quarter-end.

Original reporting
Published Oct 27, 2026, 4:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 4:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kiniksa (KNSA) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$KNSABullishHigh
01

Why it matters

The earnings beat and cash generation reinforce a bullish outlook, though future product approvals remain uncertain.

02

Market read

Earnings provide fresh data for traders to assess valuation and potential upside.

03

What to watch

Potential regulatory delays for KPL-387 and KPL-1161 could temper long‑term growth expectations.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Kiniksa (NASDAQ:KNSA) presented its Q3 2026 earnings, highlighting strong ARCALYST sales and progress on pipeline drugs.

Company-level read

Ticker impact

$KNSABullishHigh confidence
Context

Q3 earnings call disclosed $286M revenue, 58% YoY growth and $47.3M net income, the first public report of these results.

Expected impact

likely upside as investors price in robust revenue growth and cash generation

Evidence & confidence

Revenue and profit beat, cash balance of $568.8M, and guidance for $1B ARCALYST sales in 2026 support a positive move.

Market effects

Biotech sector may see broader rally on strong IL-1 inhibitor earnings.

U.S. biotech stocks could benefit from positive earnings momentum.

Limited to investors focused on specialty pharma and biotech.

Counterpoint

If guidance falls short of $1B sales, the stock could face disappointment despite current beat.

Key entities

  • Kiniksa Pharmaceuticals

    Biotech firm reporting Q3 earnings.

Related articles

$KNSAMed

Top pharma stock to watch: TD Cowen’s pick

TD Cowen identifies Kiniksa Pharmaceuticals (KNSA) as a top pick in the pharma sector, citing strong commercial momentum for Arcalyst and potential value from pipeline candidates. The firm set a $115 price target, noting underpenetrated markets and conservative revenue growth projections. KPL-387, a wholly owned drug, could add $6 to earnings per share by 2027.

$KNSAMedAI 8/10

Kiniksa Pharmaceuticals, Ltd. Q3 2026 Earnings Call Summary

Kiniksa Pharmaceuticals reported Q3 2026 revenue growth of 58% YoY, driven by increased market penetration and physician adoption of IL-1 inhibition. The company raised full-year revenue guidance to $1.045B-$1.050B. It plans to initiate a Phase I trial for KPL-1161 by year-end and expects KPL-387 Phase III data in H2 2027. Kiniksa ended the quarter with $568.8M in cash.